Details of the Drug

General Information of Drug (ID: DMS9503)

• Drug Name: Benzylpenicillin
• Synonyms: penicillin g; Benzylpenicillinic acid; Free penicillin II; Pencillin G; 61-33-6; Benzylpenicillin G; Bencilpenicilina; Benzylpenicillinum; Benzyl penicillin; Free penicillin G; Dropcillin; Pharmacillin; Gelacillin; Liquacillin; Benzopenicillin; Cilopen; Pradupen; Benzylpenicilline; Specilline G; Cilloral; Cosmopen; Ursopen; Galofak; Free benzylpenicillin; Compocillin G; Phenylacetamidopenicillanic acid; 6-(2-Phenylacetamido)penicillanic acid; Pfizerpen; Benzyl-6-aminopenicillinic acid

Indication

Disease Entry	ICD 11	Status	REF
Actinomycosis	N.A.	Approved	[1]
Acute otitis media	AB00	Approved	[2]
Anthrax	1B97	Approved	[3]
Bacterial endocarditis	N.A.	Approved	[4]
Botulism	1A11	Approved	[5]
Cervicofacial actinomycosis	N.A.	Approved	[6]
Congenital syphilis	N.A.	Approved	[7]
Cutaneous anthrax	N.A.	Approved	[8]
Erysipelas	N.A.	Approved	[9]
Erysipelothrix rhusiopathiae infectious disease	N.A.	Approved	[10]
Gastrointestinal anthrax	N.A.	Approved	[11]
Gonococcal infection of joint	N.A.	Approved	[12]
Inhalational anthrax	N.A.	Approved	[3]
Late latent syphilis	N.A.	Approved	[13]
Latent syphilis	N.A.	Approved	[14]
Latent yaws	N.A.	Approved	[15]
Listeria meningitis	N.A.	Approved	[16]
Lung abscess	N.A.	Approved	[17]
Meningococcal meningitis	N.A.	Approved	[18]
Meningococcemia	N.A.	Approved	[19]
Neonatal sepsis	N.A.	Approved	[20]
Neurosyphilis	N.A.	Approved	[21]
Pasteurella multocida infectious disease	N.A.	Approved	[22]
Pasteurellosis	N.A.	Approved	[23]
Pneumococcal meningitis	N.A.	Approved	[16]
Psoriasis	EA90	Approved	[24]
Rat-bite fever	N.A.	Approved	[25]
Respiratory tract infection	CA45	Approved	[26]
Staphylococcus aureus infection	N.A.	Approved	[27]
Streptococcal pneumonia	N.A.	Approved	[28]
Streptococcal toxic-shock syndrome	N.A.	Approved	[29]
Streptococcus infection	1B53	Approved	[30]
Syphilis	N.A.	Approved	[31]
Tertiary lesion of yaws	N.A.	Approved	[32]
Yaws	N.A.	Approved	[33]
Bejel	N.A.	Investigative	[34]
Latent early syphilis	N.A.	Investigative	[35]
Secondary syphilis	N.A.	Investigative	[36]
Tertiary syphilis	N.A.	Investigative	[37]
Tetanus	1C13	Investigative	[38]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 334.4
  Logarithm of the Partition Coefficient (xlogp); 1.8
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [39]
  Clearance: The clearance of drug is 560 mL/min in healthy humans []
  Half-life: The concentration or amount of drug in body reduced by one-half in 0.4C0.9 hours [40]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 564.6676 micromolar/kg/day [41]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.4% [40]
  Vd: The volume of distribution (Vd) of drug is 0.53-0.67 L/kg []
• Chemical Identifiers:
  Formula: C16H18N2O4S
  IUPAC Name: (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
  Canonical SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C
  InChI: InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1
  InChIKey: JGSARLDLIJGVTE-MBNYWOFBSA-N
• Cross-matching ID:
  PubChem CID: 5904
  ChEBI ID: CHEBI:18208
  CAS Number: 61-33-6
  DrugBank ID: DB01053
  TTD ID: D00QAR
  VARIDT ID: DR00488
  INTEDE ID: DR2164
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Penicillin binding protein 1 (Bact pbp)	TTTKCMH	PBPA_ECOLI ; PBPB_ECOLI ; PBPC_ECOLI	Binder	[42]
Bacterial Penicillin binding protein 3 (Bact mrcA)	TT85JMW	FTSI_ECOLI	Binder	[43]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 3A1 (SLCO3A1)	DTVNRXW	SO3A1_HUMAN	Substrate	[44]
Organic anion transporting polypeptide 4A1 (SLCO4A1)	DT8H2IC	SO4A1_HUMAN	Substrate	[44]
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[45]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[44]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[46]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[47]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[48]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Beta-lactamase (blaB)	DEV0KWQ	Q8KT52_9BACT	Substrate	[49]
N-acylhomoserine lactone acylase (lacA)	DEIU0XN	A0A0A1VBK6_9BURK	Substrate	[50]
Beta-lactamase (blaB)	DET9I1W	BLAC_BACUN	Substrate	[51]
Beta-lactamase (blaB)	DENJ2SQ	BLAB_BACFG	Substrate	[49]
Beta-lactamase (blaB)	DE37FJH	C6JIU1_FUSVA	Substrate	[49]
Beta-lactamase (blaB)	DEAILCM	A0A246EJV2_9BACT	Substrate	[52]
Beta-lactamase (blaB)	DERPJ4F	A0A2S8IKB0_BURCE	Substrate	[53]
Beta-lactamase (blaB)	DESIWFO	Q8GQK7_9FLAO	Substrate	[54]
Beta-lactamase (blaB)	DEQX0DG	Q8RIK5_FUSNN	Substrate	[55]
Beta-lactamase (blaB)	DEBAZ7H	F9DGI4_9BACT	Substrate	[52]
Beta-lactamase (blaB)	DEA5OYT	A0A4U8WDG3_9FLAO	Substrate	[56]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-fetoprotein (AFP)	OT9GG3ZI	FETA_HUMAN	Gene/Protein Processing	[57]
Annexin A8 (ANXA8)	OTLSSQCY	ANXA8_HUMAN	Gene/Protein Processing	[57]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Regulation of Drug Effects	[58]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Gene/Protein Processing	[59]
Decorin (DCN)	OTWLJL7K	PGS2_HUMAN	Gene/Protein Processing	[57]
Glutamate--cysteine ligase regulatory subunit (GCLM)	OT6CP234	GSH0_HUMAN	Gene/Protein Processing	[60]
Insulin-like growth factor II (IGF2)	OTJ4O6MW	IGF2_HUMAN	Gene/Protein Processing	[57]
Insulin-like growth factor-binding protein 5 (IGFBP5)	OTRE5V0C	IBP5_HUMAN	Gene/Protein Processing	[57]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[60]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Gene/Protein Processing	[61]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Benzylpenicillin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Benzylpenicillin and Anisindione.	Coagulation defect [3B10]	[62]

References

• [1] Abdominal actinomycosis after reparative surgery for cholecystogastric fistula in an immunosuppressed patient. BMJ Case Rep. 2021 Jul 23;14(7):e243445.
• [2] Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children with acute otitis media in Japan from 2014 to 2017. J Infect Chemother. 2019 Mar;25(3):229-232.
• [3] Human Anthrax: Update of the Diagnosis and Treatment. Diagnostics (Basel). 2023 Mar 10;13(6):1056.
• [4] Optimisation of the prevention and treatment of bacterial endocarditis. Drugs Aging. 2001;18(6):415-24.
• [5] Clinical Serum Therapy: Benefits, Cautions, and Potential Applications. Keio J Med. 2017 Dec 25;66(4):57-64.
• [6] Cervicofacial actinomycosis: a report of 14 patients observed at the Dermatology Unit of the University of Milan, Italy. Int J Dermatol. 2020 Oct;59(10):1222-1225.
• [7] Congenital syphilis in a preterm newborn with gastrointestinal disorders and postnatal growth restriction. Ital J Pediatr. 2022 Dec 29;48(1):205.
• [8] Cutaneous Anthrax. J Emerg Med. 2017 Feb;52(2):240-241.
• [9] [Streptococcus pyogenes--much more than the aetiological agent of scarlet fever]. Med Monatsschr Pharm. 2009 Nov;32(11):408-16; quiz 417-8.
• [10] Erysipelothrix rhusiopathiae bloodstream infection - A 22-year experience at Mayo Clinic, Minnesota. Zoonoses Public Health. 2017 Nov;64(7):e65-e72.
• [11] Inhalational, gastrointestinal, and cutaneous anthrax in children: a systematic review of cases: 1900 to 2005. Arch Pediatr Adolesc Med. 2007 Sep;161(9):896-905.
• [12] Infectious arthritis. Infect Dis Clin North Am. 1990 Sep;4(3):523-38.
• [13] Syphilis. Lancet. 2023 Jul 22;402(10398):336-346.
• [14] Diagnosis, treatment, and notification of syphilis during pregnancy in the state of Gois, Brazil, between 2007 and 2017. Rev Saude Publica. 2021 Oct 29;55:68.
• [15] Yaws. 2023 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 JanC.
• [16] Meningitis in adults: diagnosis and management. Intern Med J. 2018 Nov;48(11):1294-1307.
• [17] Spontaneous Clostridium perfringens lung abscess unresponsive to penicillin. Anaesth Intensive Care. 1993 Feb;21(1):117-9.
• [18] Meningococcal meningitis and diabetes insipidus. Scand J Infect Dis. 1988;20(3):341-3.
• [19] [An unusual cause of fever: chronic meningococcemia]. Ned Tijdschr Geneeskd. 1996 Apr 6;140(14):785-7.
• [20] Antibiotic regimens for early-onset neonatal sepsis. Cochrane Database Syst Rev. 2021 May 17;5(5):CD013837.
• [21] Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study. Lancet Infect Dis. 2021 Oct;21(10):1441-1447.
• [22] Pasteurella multocida pneumonia. Semin Respir Infect. 1997 Mar;12(1):54-6.
• [23] Pasteurella Multocida. 2023 May 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 JanC.
• [24] A review of antibiotics and psoriasis: induction, exacerbation, and amelioration. Expert Rev Clin Pharmacol. 2019 Oct;12(10):981-989.
• [25] Rat-Bite Fever. 2023 Mar 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 JanC.
• [26] Benzylpenicillin versus wide-spectrum beta-lactam antibiotics as empirical treatment of Haemophilus influenzae-associated lower respiratory tract infections in adults; a retrospective propensity score-matched study. Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1761-1775.
• [27] In vivo synergy between 6 beta-amidinopenicillanic acid derivatives and other antibiotics. Antimicrob Agents Chemother. 1976 Apr;9(4):589-94.
• [28] Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009 Oct 31;374(9700):1543-56.
• [29] [Beta-hemolytic streptococcal bacteremia in adults]. Duodecim. 2013;129(14):1477-84.
• [30] Prevalence and treatment of group B streptococcus colonization based on risk factors versus intrapartum culture screening. Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:178-181.
• [31] Diagnosis and treatment of syphilis in pregnant women at the services of Primary Care. Cien Saude Colet. 2022 Aug;27(8):3331-3340.
• [32] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [33] Yaws Osteoperiostitis Treated with Single-Dose Azithromycin. Am J Trop Med Hyg. 2017 May;96(5):1039-1041.
• [34] 2020 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):574-588.
• [35] Syphilis. Enferm Infecc Microbiol Clin (Engl Ed). 2019 Jun-Jul;37(6):398-404.
• [36] Secondary Syphilis. Clin Pract Cases Emerg Med. 2020 Nov;4(4):675-676.
• [37] A rare case of tertiary syphilis spondylodiscitis of the upper cervical spine: Diagnostic and therapeutic complexity, review of literature. Orthop Rev (Pavia). 2020 Jun 25;12(Suppl 1):8675.
• [38] Benzathine penicillin, metronidazole and benzyl penicillin in the treatment of tetanus: a randomized, controlled trial. Ann Trop Med Parasitol. 2004 Jan;98(1):59-63.
• [39] BDDCS applied to over 900 drugs
• [40] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [41] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [42] Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis. Biochem J. 2002 Feb 1;361(Pt 3):635-9.
• [43] Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9.
• [44] Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
• [45] Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006 Nov 15;58(11):1136-63.
• [46] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [47] Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006 May;91(1):140-9.
• [48] Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
• [49] Antimicrobial drugs used in the management of anaerobic infections in children. Drugs. 1983 Dec;26(6):520-9.
• [50] A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
• [51] Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
• [52] Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents. Antimicrob Agents Chemother. 1999 Oct;43(10):2383-8.
• [53] Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
• [54] EBR-1, a novel Ambler subclass B1 beta-lactamase from Empedobacter brevis. Antimicrob Agents Chemother. 2002 Oct;46(10):3223-7.
• [55] beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. Antimicrob Agents Chemother. 1999 May;43(5):1270-3.
• [56] Genetic and biochemical characterization of CGB-1, an Ambler class B carbapenem-hydrolyzing beta-lactamase from Chryseobacterium gleum. Antimicrob Agents Chemother. 2002 Sep;46(9):2791-6.
• [57] Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. J Appl Toxicol. 2015 Feb;35(2):205-18.
• [58] Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.
• [59] An in vitro skin sensitization assay termed EpiSensA for broad sets of chemicals including lipophilic chemicals and pre/pro-haptens. Toxicol In Vitro. 2017 Apr;40:11-25. doi: 10.1016/j.tiv.2016.12.005. Epub 2016 Dec 10.
• [60] Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):283-92.
• [61] NCTC 2544 and IL-18 production: a tool for the identification of contact allergens. Toxicol In Vitro. 2013 Apr;27(3):1127-34. doi: 10.1016/j.tiv.2012.05.018. Epub 2012 Oct 9.
• [62] Alexander DP, Russo ME, Fohrman DE, Rothstein G "Nafcillin-induced platelet dysfunction and bleeding." Antimicrob Agents Chemother 23 (1983): 59-62. [PMID: 6830209]